We used PC-3 (an androgen-independent human prostate cancer cell line lacking functional p53), LNCaP (an androgen-responsive human prostate cancer cell line with wild-type p53), and LNCaP-C4-2B (an androgen-independent variant of the LNCaP cell line) to study the role of Notch signaling in anticancer effects of SFN. Here, TP53 is linked to prostate carcinoma.